Trial Profile
Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Bayer
- 30 Mar 2009 New trial record
- 30 Mar 2009 New trial record